Stifel Financial’s Vaxcyte PCVX Stock Holding History

Stifel Financial’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16,885	Closed	-$608K	–	3672
2025 Q3	$608K	Sell	16,885 -990	-6%	-$32.8K	﹤0.01%	2694
2025 Q2	$581K	Buy	17,875 +10,440	+140%	+$342K	﹤0.01%	2688
2025 Q1	$281K	Buy	+7,435	New	+$594K	﹤0.01%	3007

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Stifel Financial's PCVX Position: Q4 2025 in Review

Stifel Financial sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 16,885 shares — an estimated $608K sold.

Stifel Financial first reported a position in PCVX in Q1 2025 and held it in 3 quarters. The position peaked at $608K in Q3 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Stifel Financial reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Stifel Financial sold 16,885 Vaxcyte shares in Q4 2025, an estimated $608K.
Stifel Financial first reported a position in Vaxcyte in Q1 2025 and held it in 3 quarters.
Stifel Financial's Vaxcyte position peaked at $608K in Q3 2025.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Stifel Financial's 13F filing for Q4 2025, filed 13 Feb 2026.